About Scailyte
Scailyte is a company based in Lucerne (Switzerland) founded in 2017 by Peter Nestorov, Daniel Sonnleithner, Manfred Claassen, and Dennis Göhlsdorf. Scailyte has raised $20.26 million across 8 funding rounds from investors including Swisscom, Zurcher Kantonalbank and HEMEX. Scailyte offers products and services including ScaiVision. Scailyte operates in a competitive market with competitors including Metabolon, Maze Therapeutics, Seer, NeoPhore and Alector, among others.
- Headquarter Lucerne, Switzerland
- Founders Peter Nestorov, Daniel Sonnleithner, Manfred Claassen, Dennis Göhlsdorf
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Scailyte Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20.26 M (USD)
in 8 rounds
-
Latest Funding Round
$8 M (USD), Series A
Dec 05, 2023
-
Investors
Swisscom
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Scailyte
Scailyte offers a comprehensive portfolio of products and services, including ScaiVision.
AI tool for analyzing multiomics data to identify clinical biomarkers
People of Scailyte
Unlock access to complete
Unlock access to complete
Funding Insights of Scailyte
Scailyte has successfully raised a total of $20.26M across 8 strategic funding rounds. The most recent funding activity was a Series A round of $8 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Scailyte
Scailyte has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Swisscom, Zurcher Kantonalbank and HEMEX.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on science and tech-driven startups
|
Locked | Locked | Locked | |
|
Regulatory affairs and marketing services are provided for healthcare entities.
|
Locked | Locked | Locked | |
|
Investments are made by Swisscom Ventures, backed by Swisscom AG.
|
Locked | Locked | Locked |
Investor details for Scailyte
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Scailyte
Investment portfolio details for Scailyte
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Scailyte
Detailed financials for Scailyte
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scailyte Comparisons
Peer comparison for Scailyte
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Scailyte
Scailyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Maze Therapeutics, Seer, NeoPhore and Alector, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| Locked | Locked | Locked |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| Locked | Locked | Locked |
Proteomics platform developed for early cancer and neurological disease detection.
|
|
| Locked | Locked | Locked |
NeoPhore is focused on cancer neoantigen evolution therapies.
|
|
| Locked | Locked | Locked |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
Detailed competitors of Scailyte
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scailyte
Complete news archive for Scailyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scailyte
Scailyte was founded in 2017.
Scailyte is headquartered in Lucerne, Switzerland. It is registered at Lucerne, Lucerne, Switzerland.
Peter Nestorov is the current CEO of Scailyte. They have also founded this company.
Scailyte is a funded company, having raised a total of $20.26M across 8 funding rounds to date.
Scailyte was founded in 2017 and is headquartered in Lucerne, Switzerland. Artificial intelligence is applied to single-cell data analysis for the discovery of novel biomarkers. Early and precise detection of complex diseases is facilitated through this technology. Mass cytometry data is also processed to identify relevant single-cell patterns. The company operates within the biotechnology and AI sectors.
Scailyte's top competitors include Alector, Lexicon Pharmaceuticals and Maze Therapeutics.
Scailyte offers ScaiVision.
Scailyte has 8 investors. Key investors include Swisscom, Zurcher Kantonalbank, HEMEX, Mirabaud, and Verve Ventures.